Related Experiment Video
Updated: Oct 10, 2026
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
Comparison of growth and morbidity outcomes in preterm infants using two different intravenous lipid emulsions
Alexyss Guy1, Austin Han2, Diana Kwiatkowski3
1Department of Pharmacy, Cleveland Clinic Children's Hospital, Cleveland, OH, USA.
Objectives:
To compare growth z-scores and prematurity-related comorbidities for preterm infants receiving Soybean Oil-Intravenous Lipid Emulsion (SO-ILE) versus Soybean + Medium-chain triglycerides + Olive + Fish oil ILE (SMOF-ILE).
Study Design:
A multicenter, retrospective cohort study of 347 preterm infants <32 weeks' gestational age with birth weight ≤1500 grams who received SO-ILE or SMOF-ILE for at least seven consecutive days.
Results:
SO-ILE group (n = 179) demonstrated significantly improved growth for length (p ≤ 0.001) and head circumference z-scores (p = 0.015) at 36 weeks' postmenstrual age and significantly worse growth for weight z-scores at 1 month (p = 0.017) compared to the SMOF-ILE group (n = 168). SO-ILE group had significantly lower rates of bronchopulmonary dysplasia (BPD) (p < 0.001) and urinary tract infections (UTI) (p = 0.045).
Conclusion:
In this population, SO-ILE had better outcomes for growth, BPD, and UTI compared to SMOF-ILE. Therefore, SO-ILE remains a reasonable lipid emulsion for preterm infants until more evidence is available.